Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Sihuan Pharmaceutical Holdings Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Sihuan Pharmaceutical Holdings Group şirketinin toplam hissedar öz sermayesi CN¥5.1B ve toplam borcu CN¥1.1B olup, bu da borç-öz sermaye oranını 21.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥11.5B ve CN¥6.4B dir.

Anahtar bilgiler

21.4%

Borç/özkaynak oranı

CN¥1.09b

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥4.86b
Eşitlik	CN¥5.09b
Toplam yükümlülükler	CN¥6.44b
Toplam varlıklar	CN¥11.53b

Son finansal sağlık güncellemeleri

Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?

Sep 30

Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?

Oct 31

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Oct 11

Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly

Sep 26

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Dec 21

Recent updates

What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You

Oct 02

Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?

Sep 30

Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year

May 31

Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

May 27

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Dec 05

Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?

Oct 31

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Aug 19

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Apr 21

Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?

Nov 03

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Oct 11

Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?

Jun 21

Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Mar 09

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Nov 28

Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly

Sep 26

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now

Jun 22

How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?

May 11

Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit

Mar 30

How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?

Mar 07

Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?

Feb 07

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Jan 11

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Dec 21

Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters

Dec 07

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 460 'nin kısa vadeli varlıkları ( CN¥6.7B ) kısa vadeli yükümlülüklerini ( CN¥4.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: 460 şirketinin kısa vadeli varlıkları ( CN¥6.7B ) uzun vadeli yükümlülüklerini ( CN¥2.3B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 460 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 460 şirketinin borç/öz sermaye oranı son 5 yılda 0.2% seviyesinden 21.4% seviyesine yükseldi.

Borç Kapsamı: 460 'nin borcu işletme nakit akışı ( 19.1% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: 460 şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

Sihuan Pharmaceutical Holdings Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?

Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Recent updates

What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You

Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?

Upcoming dividend of HK$0.021 per share

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration

New major risk - Revenue and earnings growth

Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA

Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year

Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Now 21% undervalued after recent price drop

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Investor sentiment deteriorated over the past week

Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.016 per share

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection